EP3994136 - PYRROLO [2, 3-B] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 08.04.2022 Database last updated on 24.08.2024 | |
Former | The international publication has been made Status updated on 15.01.2021 | Most recent event Tooltip | 26.07.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states BeiGene, Ltd. C/o Mourant Governance Services (Cayman) Limited 94 Solaris Avenue, Camana Bay Grand Cayman KY1-1108 / KY | [2022/19] | Inventor(s) | 01 /
LI, Jing No. 30 Science Park Road, Zhongguancun Life Science Park Changping Beijing 102206 / CN | 02 /
XU, Sanjia No. 30 Science Park Road, Zhongguancun Life Science Park Changping Beijing 102206 / CN | 03 /
WANG, Zhiwei No. 30 Science Park Road, Zhongguancun Life Science Park Changping Beijing 102206 / CN | [2022/26] |
Former [2022/19] | 01 /
WANG, Zhiwei No. 30 Science Park Road Zhongguancun Life Science Park, Changping Beijing 102206 / CN | ||
02 /
XU, Sanjia No. 30 Science Park Road Zhongguancun Life Science Park, Changping Beijing 102206 / CN | |||
03 /
LI, Jing No. 30 Science Park Road Zhongguancun Life Science Park, Changping Beijing 102206 / CN | Representative(s) | Mewburn Ellis LLP Aurora Building Counterslip Bristol BS1 6BX / GB | [2022/19] | Application number, filing date | 20834932.4 | 03.07.2020 | [2022/19] | WO2020CN100037 | Priority number, date | WO2019CN94749 | 04.07.2019 Original published format: PCT/CN2019/094749 | WO2019CN123268 | 05.12.2019 Original published format: PCT/CN2019/123268 | WO2020CN89498 | 09.05.2020 Original published format: PCT/CN2020/089498 | [2022/19] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021000925 | Date: | 07.01.2021 | Language: | EN | [2021/01] | Type: | A1 Application with search report | No.: | EP3994136 | Date: | 11.05.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 07.01.2021 takes the place of the publication of the European patent application. | [2022/19] | Search report(s) | International search report - published on: | CN | 07.01.2021 | (Supplementary) European search report - dispatched on: | EP | 31.05.2023 | Classification | IPC: | C07D487/04, C07D519/00, A61P35/00 | [2023/26] | CPC: |
A61P35/00 (EP,CN,IL,KR);
C07D487/04 (EP,CN,IL,KR,US);
A61K31/4985 (KR);
C07D519/00 (EP,CN,IL,US);
C07F9/6561 (CN)
|
Former IPC [2022/19] | C07D471/00, C07D487/00, C07D487/04, C07D487/02, A61K31/517, A61K31/519, A61K31/437, A61P35/00 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/19] | Title | German: | PYRROLO[2, 3-B]PYRAZINE ALS HPK1-INHIBITOR UND VERWENDUNG DAVON | [2022/19] | English: | PYRROLO [2, 3-B] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF | [2022/19] | French: | PYRROLO[2, 3-B]PYRAZINES UTILISÉES EN TANT QU'INHIBITEUR DE HPK1 ET LEUR UTILISATION | [2022/19] | Entry into regional phase | 23.12.2021 | National basic fee paid | 23.12.2021 | Search fee paid | 23.12.2021 | Designation fee(s) paid | 23.12.2021 | Examination fee paid | Examination procedure | 23.12.2021 | Examination requested [2022/19] | 15.12.2023 | Amendment by applicant (claims and/or description) | 15.12.2023 | Date on which the examining division has become responsible | Fees paid | Renewal fee | 22.06.2022 | Renewal fee patent year 03 | 23.06.2023 | Renewal fee patent year 04 | 25.07.2024 | Renewal fee patent year 05 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y]WO2006015124 (SGX PHARMACEUTICALS INC [US], et al) [Y] 1-16 * Page 134 last compound;; claims 28-31 *; | [Y]CN106336413 (GUANGDONG HEC PHARMACEUTICAL) [Y] 1-16* compounds 3, 4, 5, *; | [Y]WO2018049152 (INCYTE CORP [US], et al) [Y] 1-16 * claims 1-46, 49-52, 55-59 *; | [Y]WO2018049200 (INCYTE CORP [US]) [Y] 1-16 * claims 1-46, 59-61 *; | [Y]WO2018049214 (INCYTE CORP [US]) [Y] 1-16 * claims 1-46 * |